{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-23-000068","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.028990+00:00","generated_at":"2026-06-10T21:58:05.398619+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Labcorp EVP Kirchgraber resigns, receives $2.75M severance and equity acceleration","bullets":["Paul Kirchgraber, Sr. Advisor to CEO and former head of Drug Development, resigned effective Sept 1, 2023.","Severance payment of $2,748,997 (2x salary plus average bonus) plus $20,600 medical stipend, $3,000 outplacement.","Equity: RSUs/options vesting within 12 months vest on separation; performance awards continue prorated.","Departure treated as 'good reason' under Labcorp's Severance Plan; includes non-compete/non-solicit."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-23-000068","json":"https://secwatch.observer/filing/0000920148-23-000068.json","markdown":"https://secwatch.observer/filing/0000920148-23-000068.md","text":"https://secwatch.observer/filing/0000920148-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000068/0000920148-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000068/lh-20230908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:58:05.398619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d955a23f1","claim":"Paul Kirchgraber resigned as Senior Advisor to the CEO at LABCORP HOLDINGS INC..","evidence_excerpt":"As previously disclosed, on January 4, 2023, Paul Kirchgraber, Senior Advisor to the CEO, and former EVP and CEO of Labcorp’s Drug Development business segment, informed Laboratory Corporation of America Holdings (“Labcorp”) that he intended to depart Labcorp upon the completion of the spin-off of Fortrea Holdings Inc. in order to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000068/0000920148-23-000068-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Advisor to the CEO"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}